Oncolys BioPharma

What Oncolys BioPharma does

Oncolys BioPharma Inc. is a Tokyo-headquartered, publicly-traded Japanese biopharmaceutical company (TSE Growth Market: 4588) founded in 2004 by Yasuo Urata, focused on the discovery, development, and commercialization of oncolytic virus therapies and virus-based diagnostics for cancer. The company's proprietary platform is built on telomerase-specific replication-competent adenovirus type 5 technology, which selectively replicates in and lyses cancer cells while sparing normal tissue due to low telomerase activity in healthy cells. Its lead asset, OBP-301 (suratadenoturev, brand name Telomelysin), received standard manufacturing and marketing approval from Japan's MHLW in June 2026 for the treatment of unresectable esophageal cancer — making it Japan's first approved oncolytic adenovirus therapy and the company's first commercial product. The pipeline extends across next-generation oncolytic viruses (OBP-702, armed with p53 for 10-30x stronger anti-tumor activity), cancer diagnostics (OBP-401/OBP-1101 Telomescan for circulating tumor cell detection), antivirals (OBP-601/Censavudine for neurodegenerative disease via LINE-1 inhibition, licensed to Transposon Therapeutics; OBP-2011 for COVID-19 via nucleocapsid inhibition), and a repositioned HDAC inhibitor (OBP-801, now in ophthalmology research).

The company operates a hybrid revenue model combining licensing/royalty income from out-licensed assets (notably the $300M+ Transposon deal for OBP-601) with co-promotion product sales following the Telomelysin approval. Commercial distribution in Japan is handled exclusively by FUJIFILM Toyama Chemical under a February 2024 sales partnership that provides hospital access, promotional infrastructure, and NHI pricing negotiation support. R&D is anchored at the Kobe Research Lab on Port Island, with wholly-owned US subsidiaries (Oncolys USA Inc. in Delaware since 2016 and OPA Therapeutics Inc. in California since 2020) supporting US licensing and next-generation development. End customers are healthcare institutions and oncologists at major cancer centers in Japan, with clinical research collaborations spanning Okayama University, National Cancer Center East, Juntendo University, and Kagoshima University. Customer concentration is high by virtue of single-partner commercial distribution and a single-counterparty licensing deal; the company has 11-50 employees, a founder-CEO-led management team, and a previously disclosed substantial cash position supporting the post-launch commercial and pipeline expansion phase.

Name

Oncolys BioPharma

Legal name

オンコリスバイオファーマ株式会社

Website

https://oncolys.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Oncolys BioPharma is a Tokyo-based clinical-stage and newly commercial Japanese biopharma developing telomerase-specific oncolytic adenovirus therapies and virus-based cancer diagnostics. Its lead product, Telomelysin (OBP-301), received Japan PMDA approval in June 2026 for esophageal cancer, commercialized via FUJIFILM Toyama Chemical.

Ownership category

akta.pro rank

Product category

Cancer Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

akta.pro secondary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

Keywords

• Oncolytic virus therapy
• Cancer biopharmaceuticals
• Viral gene therapy
• Cancer diagnostic tests
• Antiviral drug development

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Licensing Revenue: Contract-based licensing model where Oncolys develops compounds to certain stages and partners with pharmaceutical companies for remaining development and commercialization. Receives milestone payments tied to development progress and royalty payments based on product sales.
2. Product Sales: Following OBP-301 approval, the company transitioned from pure licensing to a hybrid model including direct product sales through co-promotion with Fujifilm Toyama Chemical.
3. Collaboration Revenue: Revenue from co-development arrangements including development support payments and research collaborations with academic institutions and pharmaceutical partners.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Oncolys BioPharma develops virus-based therapeutics and diagnostics for cancer and serious viral diseases. Its lead marketed product, Telomelysin (OBP-301, generic suratadenoturev), is Japan's first approved oncolytic adenovirus therapy, indicated for esophageal cancer. The company also maintains a pipeline of next-generation oncolytic viruses (OBP-702), cancer detection viruses (OBP-401/OBP-1101 Telomescan), an HDAC inhibitor (OBP-801), and antiviral candidates (OBP-601 Censavudine, OBP-2011).

Product overview

Oncolys BioPharma is a biopharmaceutical company developing virus-based therapeutics and diagnostics. The company operates two core platforms: oncolytic virus therapy for cancer treatment (OBP-301, OBP-702) and antiviral drugs for severe viral infections (OBP-601, OBP-2011), plus cancer diagnostic tests (OBP-401, OBP-1101). Telomelysin®注 (OBP-301) received manufacturing and marketing approval in June 2026 as Japan's first oncolytic adenovirus therapy for esophageal cancer.

Differentiator

Problem solved

Functional benefit

Brands

• Telomelysin (テロメライシン): OBP-301 oncolytic virus therapy product for esophageal cancer treatment, approved in Japan in June 2026
• Telomescan (テロメスキャン)
• OBP-301

Products and services

• Telomelysin Injection (OBP-301, suratadenoturev) Approved injectable oncolytic adenovirus therapy for the treatment of unresectable esophageal cancer in combination with radiation therapy. The first oncolytic adenovirus therapy approved in Japan; sold to hospitals and cancer centers through Fujifilm Toyama Chemical's distribution network.
• Telomescan (OBP-401 / OBP-1101) Cancer diagnostic test using telomerase-specific adenovirus carrying a fluorescent reporter gene (GFP) or engineered fiber to detect circulating tumor cells (CTCs) in blood samples. Intended for cancer detection and liquid biopsy applications in research and clinical settings.

Quantifiable outcome

• Phase 2 trials showed approximately 60% local complete response rate for esophageal cancer with OBP-301 + radiation combination, compared to ~30% with radiation alone
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Fujifilm Toyama Chemical Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 1 February 2024Fujifilm Toyama Chemical serves as the sales promotion partner for Telomelysin (OBP-301) in Japan following June 2026 approval. The partnership involves co-promotion activities including promotional material development, hospital procurement negotiations, launch symposiums, and nationwide product distribution.
• Transposon Therapeutics, Inc.coreStrategic or Co-development Partner · 1 June 2020Licensed OBP-601 (Censavudine/TPN-101) worldwide with sublicense rights for neurological diseases including PSP, ALS, and FTD. Deal valued at over $300 million USD in upfront and milestone payments plus royalties. Transposon, backed by venture capital and Brown University technology, funds all development costs.
• Kagoshima UniversitycoreStrategic or Co-development Partner · 1 June 2020Patent transfer agreement for OBP-2011 coronavirus treatment development. Long-standing collaboration on antiviral drug development including HIV, HCV, and HBV with Prof. Masanori Baba's Retrovirus Research Center.
• OPA Therapeutics Inc.minorOthers · 1 March 2020Wholly-owned subsidiary established in California for third-generation oncolytic virus development and West Coast biotech operations.
• Chugai Pharmaceutical Co., Ltd.minorStrategic or Co-development Partner · 8 April 2019Exclusive licensing partnership for OBP-301 in Japan and Taiwan with option rights, signed in April 2019. Partnership concluded in October 2021 with development rights returned to Oncolys BioPharma. During partnership, Chugai conducted Phase 2 trials and bore development costs.
• Juntendo UniversitycoreStrategic or Co-development Partner · 1 November 2017Joint research collaboration for OBP-401/OBP-1101 practical application focusing on circulating tumor cell (CTC) detection and cancer liquid biopsy applications. Established collaborative research department within the university.
• Oncolys USA Inc.coreOthers · 1 September 2016Wholly-owned US subsidiary established in Delaware to accelerate licensing activities and clinical development in North America. Operates from New Jersey area.
• Astellas Pharma Inc.minorOEM/ Whitelabel/ Licensing Partner · 1 October 2009Licensed OBP-801 (HDAC inhibitor) worldwide from Astellas Pharma for development as a novel molecular targeted anticancer agent. Company received capital participation from Astellas.
• Medigen Biotechnology Corp. (Taiwan)minorStrategic or Co-development Partner · 1 March 2008Strategic partnership for OBP-301 development and commercialization in Taiwan and related markets.

Scale indicators7 records

Recent moves9 records

Expansion highlights5 records

Direct peers

• PsiOxus Therapeutics: PsiOxus develops enadenotucirev, an oncolytic adenovirus platform (now called ngly1) being tested in multiple solid tumor indications including in combination with checkpoint inhibitors. It is a direct peer to Oncolys in the oncolytic adenovirus space targeting solid tumors.
• Amgen: Amgen commercializes Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy (for melanoma). It is the most directly comparable commercial-stage oncolytic virus company globally and a critical reference point for Telomelysin's launch trajectory, pricing, and physician adoption patterns.
• Vyriad: Vyriad develops oncolytic vesicular stomatitis virus (VSV) and measles virus platforms for solid tumors, including combination therapy programs with checkpoint inhibitors. It is comparable as a clinical-stage oncolytic virus developer focused on solid tumor immunotherapy.
• DNAtrix: DNAtrix develops DNX-2401 (tasadenoturev), an oncolytic adenovirus for glioblastoma and other solid tumors, using a tumor-selective adenovirus platform that closely parallels Oncolys's telomerase-targeted approach.
• Turnstone Biologics: Turnstone Biologics develops oncolytic virus immunotherapies (including the Seprehvir/hVIP combination platform) for solid tumors, with active clinical programs in combination with checkpoint inhibitors. It is a peer in the oncolytic virus + immune checkpoint combination space.
• Sorrento Therapeutics: Sorrento has pursued multiple oncology platforms including oncolytic virus programs and cellular therapies, positioning it as a broad peer in the virus-based cancer treatment space relevant to Oncolys's pipeline.
• Genelux Corporation: Genelux is a clinical-stage oncolytic virus company developing GL-ONC1 (Olvi-Vec) and other vaccinia- and adenovirus-based candidates for solid tumor treatment. Like Oncolys, it uses genetically modified viruses to selectively replicate in and destroy cancer cells.
• Lokon Pharma: Lokon Pharma develops the LOAd (Locked-On Adenovirus) platform of oncolytic adenoviruses armed with immunostimulatory transgenes for cancer treatment, directly comparable to Oncolys's OBP-702 next-generation p53-armed adenovirus platform.

Broad incumbents

• Daiichi Sankyo: Daiichi Sankyo is a major Japanese pharmaceutical company with significant oncology franchises and ADC platform leadership (Enhertu). It is comparable to Oncolys as a Japan-headquartered oncology drug developer, but at a vastly larger scale and broader portfolio.
• Astellas Pharma: Astellas is a global Japanese pharmaceutical company and an existing Oncolys partner (licensed OBP-801 to Oncolys and holds 2.48% equity). It represents a comparable large Japanese pharma with broad oncology and specialty therapeutics franchises, and a potential strategic acquirer or commercialization partner.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/oncolys-biopharma-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncolys BioPharma